Follow the people · Insider
Mary Miller
Mary Miller files insider transactions with the SEC as a chief legal officer of Acrivon Therapeutics (ACRV). We hold 2 disclosed purchases and sales filed since 16 February 2021, 2 of them in the last 90 days.
- Files forACRV
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure20 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 26 September 2023 — 18 August 2026Chief Legal Officer · Acrivon Therapeutics (ACRV)36 Form 4 lines · source: SEC Form 4
- Filed 12 February 2021 — 22 March 2022General Counsel & Corp Sec · Butterfly Network (BFLY)6 Form 4 lines · source: SEC Form 4
Everything they disclosed
42 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 185 shares of Acrivon TherapeuticsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 573 shares of Acrivon TherapeuticsSEC Form 423 July 2026Common Stock · traded 21 July 2026 · filed 23 July 2026
- was granted 49,830 shares of Acrivon TherapeuticsSEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 418 May 2026Common Stock · traded 14 May 2026 · filed 18 May 2026
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- was granted 129,760 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- was granted 129,760 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- had shares withheld for tax on 217 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 217 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 659 shares of Acrivon TherapeuticsSEC Form 421 January 2026Common Stock · traded 17 January 2026 · filed 21 January 2026
- had shares withheld for tax on 659 shares of Acrivon TherapeuticsSEC Form 421 January 2026Common Stock · traded 17 January 2026 · filed 21 January 2026
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 418 November 2025Common Stock · traded 14 November 2025 · filed 18 November 2025
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 421 October 2025Common Stock · traded 17 October 2025 · filed 21 October 2025
- had shares withheld for tax on 284 shares of Acrivon TherapeuticsSEC Form 43 October 2025Common Stock · traded 1 October 2025 · filed 3 October 2025
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 418 August 2025Common Stock · traded 14 August 2025 · filed 18 August 2025
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 421 July 2025Common Stock · traded 17 July 2025 · filed 21 July 2025
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 416 May 2025Common Stock · traded 14 May 2025 · filed 16 May 2025
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 418 April 2025Common Stock · traded 17 April 2025 · filed 18 April 2025
- was granted 15,616 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 April 2025Stock Option (Right to Buy) · traded 1 April 2025 · filed 3 April 2025
- was granted 93,693 shares of Acrivon Therapeutics (a derivative holding)SEC Form 44 March 2025Stock Option (Right to Buy) · traded 1 March 2025 · filed 4 March 2025
- had shares withheld for tax on 217 shares of Acrivon TherapeuticsSEC Form 419 February 2025Common Stock · traded 14 February 2025 · filed 19 February 2025
- had shares withheld for tax on 659 shares of Acrivon TherapeuticsSEC Form 422 January 2025Common Stock · traded 17 January 2025 · filed 22 January 2025
- was granted 67,567 shares of Acrivon Therapeutics (a derivative holding)SEC Form 427 November 2024Stock Option (Right to Buy) · traded 1 March 2024 · filed 27 November 2024
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 418 November 2024Common Stock · traded 14 November 2024 · filed 18 November 2024
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 421 October 2024Common Stock · traded 17 October 2024 · filed 21 October 2024
- had shares withheld for tax on 284 shares of Acrivon TherapeuticsSEC Form 43 October 2024Common Stock · traded 1 October 2024 · filed 3 October 2024
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 416 August 2024Common Stock · traded 14 August 2024 · filed 16 August 2024
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 419 July 2024Common Stock · traded 17 July 2024 · filed 19 July 2024
- had shares withheld for tax on 184 shares of Acrivon TherapeuticsSEC Form 416 May 2024Common Stock · traded 14 May 2024 · filed 16 May 2024
- had shares withheld for tax on 558 shares of Acrivon TherapeuticsSEC Form 419 April 2024Common Stock · traded 17 April 2024 · filed 19 April 2024
- had shares withheld for tax on 217 shares of Acrivon TherapeuticsSEC Form 416 February 2024Common Stock · traded 14 February 2024 · filed 16 February 2024
- had shares withheld for tax on 652 shares of Acrivon TherapeuticsSEC Form 419 January 2024Common Stock · traded 17 January 2024 · filed 19 January 2024
- had shares withheld for tax on 735 shares of Acrivon TherapeuticsSEC Form 416 November 2023Common Stock · traded 14 November 2023 · filed 16 November 2023
- had shares withheld for tax on 2,232 shares of Acrivon TherapeuticsSEC Form 419 October 2023Common Stock · traded 17 October 2023 · filed 19 October 2023
- was granted 11,576 shares of Acrivon Therapeutics (a derivative holding)SEC Form 428 September 2023Stock Option (Right to Buy) · traded 26 September 2023 · filed 28 September 2023
- was granted 3,858 shares of Acrivon TherapeuticsSEC Form 428 September 2023Common Stock · traded 26 September 2023 · filed 28 September 2023
- was granted 54,789 shares of Butterfly NetworkSEC Form 424 March 2022Class A Common Stock · traded 22 March 2022 · filed 24 March 2022
- was granted 189,655 shares of Butterfly NetworkSEC Form 48 March 2022Class A Common Stock · traded 4 March 2022 · filed 8 March 2022
- ▼ sold on the open market 16,677 shares of Butterfly NetworkSEC Form 417 February 2022Common Stock · traded 16 February 2022 · filed 17 February 2022
- was granted 155,745 shares of Butterfly NetworkSEC Form 425 February 2021Class A Common Stock · traded 12 February 2021 · filed 25 February 2021
- was granted 259,575 shares of Butterfly Network (a derivative holding)SEC Form 425 February 2021Stock Option (right to buy) · traded 12 February 2021 · filed 25 February 2021
- was granted 259,575 shares of Butterfly Network (a derivative holding)SEC Form 416 February 2021Stock Option (right to buy) · traded 12 February 2021 · filed 16 February 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.